about
Corticosteroids for treating sepsisCorticosteroids for treating severe sepsis and septic shockCorticosteroids in acute respiratory failureThe origin and functions of multiple human glucocorticoid receptor isoformsCanadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.Identification of novel biomarkers in seasonal allergic rhinitis by combining proteomic, multivariate and pathway analysis.How to manage difficult asthma cases. An action plan for physicians and patients.Molecular mechanisms of corticosteroids in allergic diseases.Systemic corticosteroid therapy for acute asthma exacerbations.Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults.Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS.Mitogen-activated protein kinases and asthma.Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance.A rational approach to the management of severe refractory asthma.DAX-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X-chromosome, gene 1) selectively inhibits transactivation but not transrepression mediated by the glucocorticoid receptor in a LXXLL-dependent manner.Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma.Glucocorticoid-resistant asthma: more than meets the eye.Blockade of interleukin-6 receptor enhances the anti-arthritic effect of glucocorticoids without decreasing bone mineral density in mice with collagen-induced arthritis.Efficacy and safety of inhaled corticosteroids. New developments.Increased sensitivity to glucocorticoids in peripheral blood mononuclear cells of chronic fatigue syndrome patients, without evidence for altered density or affinity of glucocorticoid receptors.Induction of apoptosis in nasal polyp fibroblasts by glucocorticoids in vitro.Omalizumab (Xolair) in patients with steroid-resistant asthma: lessons to be learnt.Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose.Corticosteroid unresponsiveness in asthma: primary or acquired?
P2860
Q24187207-09F35CE3-817E-40B5-911A-311369DFEED2Q24247427-FD4FE040-FC3A-49E1-BD3A-AD59ED215D20Q28145486-82945E98-3338-43AF-BBF3-A951B889EA4DQ28273092-FBE7D39F-2FC7-4CD9-8AED-643B8532F392Q33976334-38D9479C-26FB-45A2-9508-FE8C0C3403CCQ34009395-D88C7E36-B6DF-400F-A2A6-BA1D6F382F20Q34267156-D5827604-5D8C-4163-BBDD-CA849443D603Q34383896-3E713207-4B74-4E52-AB8A-C5EF8975F6CCQ34541967-75E498EE-5693-4159-BBCD-42DB82F4D920Q34834695-9753FDE3-0651-4F22-8846-C1E9C808FF74Q35841868-D504E290-8172-40D9-8BA4-86DDAFE1BDF1Q35865902-743ADAB2-1F8C-4FC3-8312-5C4CF853EE21Q36239990-E757B903-3E40-44BB-867F-46903C289F54Q36334802-77215107-F026-4D7B-A57C-541B6127C394Q36756451-40A47239-12B1-4FBB-9E16-9F6493810A4FQ37383777-A5EB7331-5C35-4A01-945C-90EBAEEC5CEDQ38127243-F2C9392E-ACFB-4893-877A-CDE0659FF888Q38850404-6877CF01-6ACC-474F-8EEB-552CE0312015Q41728966-D24F1CCE-F7B5-4613-88F6-3C6CCBB10421Q43565888-E1764E43-76B2-4659-8716-EB0A479BA9ABQ44718521-147E3FB1-55CB-4AAC-A718-A4BF1E21C880Q46935366-C08DED82-25B5-4F73-8891-A84A406DE930Q47718858-80900692-F5DC-4683-A6B6-A66A17B76CBAQ54146569-9561C214-3B2E-4547-AF8E-BC9769A7250A
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Glucocorticoid resistance in asthma.
@en
type
label
Glucocorticoid resistance in asthma.
@en
prefLabel
Glucocorticoid resistance in asthma.
@en
P2093
P2860
P356
P1476
Glucocorticoid resistance in asthma.
@en
P2093
Crompton GK
Greening AP
P2860
P304
P356
10.1164/AJRCCM/152.6_PT_2.S125
P407
P433
P577
1995-12-01T00:00:00Z